

Patient Name	Date of Birth	Allergies / Sensitivities (or state if none known)	Number of syringe pump charts in use (If 2 syringe pumps are in use, use a separate chart for each one and cross reference)
Address	NHS Number		

Continuous Subcutaneous Syringe Pump Prescription 1					Administration Record					
					Syringe pump asset number:					
Medicine	Initial dose over 24 hours	Dose/ Range over 24 hours			Date					
					Start Time					
					Dose A					
					Dose B					
					Dose C					
					Dose D					
Diluent		Route		Additional instructions		Total volume in syringe (ml)				
Water for Injection / Sodium Chloride 0.9% Injection (<i>delete</i>)		SC				Syringe size				
Cross through any blank lines A to D to prevent changes to prescription after signing. If a change to the medicines / doses is required rewrite in a new prescription section						Line primed Y / N				
						Rate displayed (ml / hr)				
Prescriber's signature			Print Name			Battery %				
						Site check (tick)				
Date	Time	Discontinue date	Time	Sign	Sign / Print					

Continuous Subcutaneous Syringe Pump Prescription 2					Administration Record					
					Syringe pump asset number:					
Medicine	Initial dose over 24 hours	Dose/ Range over 24 hours			Date					
					Start Time					
					Dose A					
					Dose B					
					Dose C					
					Dose D					
Diluent		Route		Additional instructions		Total volume in syringe (ml)				
Water for Injection / Sodium Chloride 0.9% Injection (<i>delete</i>)		SC				Syringe size				
Cross through any blank lines A to D to prevent changes to prescription after signing. If a change to the medicines / doses is required rewrite in a new prescription section						Line primed Y / N				
						Rate displayed (ml / hr)				
Prescriber's signature			Print Name			Battery %				
						Site check (tick)				
Date	Time	Discontinue date	Time	Sign	Sign/ Print					

Principles of anticipatory prescribing

- This guidance provides general recommendations for the pharmacological management of common symptoms in the last days of life.
- Reversible causes of symptoms should be treated where appropriate.
- Non-pharmacological methods should also be considered e.g. re-positioning to manage respiratory secretions, ensuring adequate hydration, where appropriate.
- Involve the dying person and those important to them in making decisions about symptom control in the last days of life where possible.
- Use an individualised approach to prescribing anticipatory medicines for people who are likely to need symptom control.
- Assess what medicines the person might need to manage symptoms likely to occur during their last days of life (e.g. pain, breathlessness, nausea and vomiting, anxiety/agitation/delirium and respiratory secretions)
- When deciding which anticipatory medicines to offer take into account:
 - The likelihood of specific symptoms occurring
 - The likely cause of symptoms
 - The dying person's preferences
 - The benefits and harms of prescribing or administering medicines
 - The benefits and harms of not prescribing or administering medicines
 - The possible risk of the person suddenly deteriorating (for example catastrophic haemorrhage or seizures) for which urgent symptom control may be needed
 - The place of care and the time it would take to obtain medicines.
 - Ensure that suitable anticipatory medicines are prescribed as early as possible.
- Specify the indications for use and the dosage of any medicines prescribed and start with the lowest effective dose.
- Specify an appropriate route for administration. If the person is unable to take or tolerate oral medication, give subcutaneous injections.
- Consider giving continuous medication via a syringe pump if more than 2 or 3 doses of 'as required' medicines have been given within 24 hours.
- Review these medicines as the dying person's needs change and regularly reassess symptoms to inform appropriate titration of medicine
- If anticipatory medicines are administered, monitor for benefits and any side effects at least daily, and adjust the individualised care plan and prescription as necessary.

References

NICE NG31 Care of Dying Adults in the Last Days of Life Dec 2015
 NICE CG140 Palliative Care for Adults: Opioids for Pain Relief May 2012 (updated Aug 16)
 Palliative Care Formulary
<https://www.medicinescomplete.com/#/content/palliative>
 Palliative Care Adult Network Guidelines Accessed 29/5/20
<https://book.pallcare.info/index.php>
 DHSC Supply Disruption Alert – Update SDA/2020/003(U)

<https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103005>

N.B This Guidance is to be used in parallel with the **BLMK Information to support GPs managing patients who are or will become Palliative and require EOL care due to COVID 19**

Medication supply – updated in line with CAS Supply Disruption alert SDA/2020/003(U)

Drug	Supply	Strength
Morphine sulphate if opioid naïve†	TEN	10mg/1ml ampoules
Midazolam	TEN	10mg/2ml ampoules
Lorazepam tablets (Genus brand)	TEN	1mg tablets (used sublingually)
Cyclizine	TEN	50mg/1ml ampoules
Haloperidol	TEN	5mg/1ml ampoules
Glycopyrronium	TEN	200 micrograms/1ml ampoules
Water for injection	TWENTY	10ml ampoules

†Seek advice on appropriate quantity for patients already taking regular opioids or alternative opioids.

Quantities prescribed are at the clinical discretion of the prescriber as stated quantities may not be suitable for all patients.

For community patients, all drugs should be transcribed onto the community authorisation and administration forms.

Specialist Palliative Care (SPC) Advice

Seek advice if there is uncertainty about the cause of symptoms, if symptoms do not improve with treatment or there are undesirable side effects.

Service	Daytime	24/7 Advice Line
Luton and Dunstable Hospital SPC Team	01582 497522 Monday - Friday	0808 180 7788
Keech Hospice	01582 492339	
Luton Community SPC Team (CCS)	0333 405 3000 Everyday 9-5	

Extended hours pharmacies:

Community pharmacies who will stock anticipatory medication: <https://pcm.prescqipp.info/>

*CSCI = continuous subcutaneous infusion

Version 2: Approved by CCS NHS Trust Medication Safety and Governance Group 8th June 2020
 Luton Prescribing Committee 11th June 2020 Review date: June 2023

Indication	Drug	PRN subcutaneous (s/c) dose	Syringe pump dose (CSCI* / 24 hours)	Think box
Pain <i>If opioid naïve</i>	1st line Morphine for all patients	2.5 – 5mg s/c 2-4 hourly	10 -20mg / 24 hours	Treat reversible causes e.g. urinary retention.
	Diamorphine Reserved Only for specific clinical circumstances in which its greater solubility is required	2.5 – 5mg s/c 2-4 hourly	10 – 20mg / 24 hours	Consider co-analgesics e.g. Paracetamol. Consider reducing dose and frequency or using an alternative opioid in renal failure or frailty.
Pain <i>If already on regular oral Morphine</i>	1st line Morphine for all patients	Divide the total oral Morphine dose by 12 and administer this dose subcutaneously e.g. 30mg MST BD = 60mg divide by 12 = 5mg s/c 2-4 hourly	Half of the total oral Morphine dose e.g. 30mg MST BD 60mg divide by 2 30mg Morphine/ 24 hours	If the patient is already on an alternative opioid or analgesic patch seek specialist advice or review opioid conversion guidance. The SC prn dose should be 1/6th - 1/10th of total 24h intake SC Remember to take account of Fentanyl patches
	Diamorphine Reserved Only for specific clinical circumstances in which its greater solubility is required	Divide the total oral Morphine dose by 18 and administer this dose subcutaneously e.g. 30mg MST BD = 60mg divide by 18 = 2.5-5mg s/c 2-4 hourly	Divide the total oral Morphine dose by 3 and administer this dose over 24 hours subcutaneously e.g. 30mg MST BD = 60mg divide by 3 20mg Diamorphine / 24 hours	Reserve diamorphine for situations in which its greater solubility is required
Breathlessness	1st line Morphine for all patients	2.5mg s/c 2-4 hourly (if opioid naïve)	5-10mg/ 24 hours (if opioid naïve)	Only offer oxygen for hypoxaemia.
	Diamorphine Reserved Only for specific clinical circumstances in which its greater solubility is required	2.5mg s/c 2-4 hourly (if opioid naïve)	10mg / 24 hours (if opioid naïve)	May need both an opioid and benzodiazepine. Genus brand of Lorazepam is preferred as it dissolves faster when given sublingually.
	Midazolam	2.5mg s/c 2-4 hourly	5-15mg / 24 hours	
	Lorazepam	500 micrograms - 1mg sublingual 6 hourly Tablets used off label sublingually	N/A	
Nausea and vomiting	1st line Cyclizine	50mg s/c 8 hourly	100-150mg / 24 hours	Caution in heart failure. For bowel obstruction seek specialist advice.
	2nd line Haloperidol	500 micrograms -2.5mg s/c 2 – 4 hourly	1.5-5mg / 24 hours	Caution with haloperidol in Parkinson's.
Anxiety, delirium and agitation	Midazolam	2.5 – 5mg s/c 2 hourly	10 – 30mg / 24 hours	Treat reversible causes e.g. pain, urinary retention. Consider level of sedation required.
	Lorazepam (Genus brand)	500micrograms – 1mg sublingual 6 hourly Tablets used off label sublingually	N/A	Consider benzodiazepines for anxiety / agitation and anti- psychotics for delirium / agitation.
	Haloperidol	500micrograms – 3mg s/c 2 hourly	1.5mg – 10mg / 24 hours	Caution with haloperidol in Parkinson's.
Noisy respiratory secretions	Glycopyrronium Bromide	200 micrograms – 400micrograms s/c 6 hourly	600 micrograms – 1.2mg / 24 hours	Reposition patient. Reassure relatives and only use medications if secretions are causing distress. Consider switching / stopping if no benefit after 24 hours.
Seizures	Midazolam	10mg s/c stat (repeat once after 15-20 minutes if seizures persist)	20-30mg / 24 hours	Replace oral anticonvulsive drugs with midazolam in syringe pump if no longer able to swallow.
	Buccal Midazolam	10mg buccally stat	N/A	If on oral steroids for cerebral disease seek specialist advice on converting these to parenteral route.
Severe haemorrhage	Midazolam	10mg s/c/IM or buccally stat	N/A	Manage distress in acute, severe bleeding. For on-going bleeding, treat any distress or pain as detailed.

